{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:42:24Z","timestamp":1792788144986,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Mike and Valeria Rosenbloom Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02525-3","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T13:32:56Z","timestamp":1734615176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Hemoglobin A1c and abdominal obesity as predictors of diabetes and ASCVD in individuals with prediabetes in UK Biobank: a prospective observational study"],"prefix":"10.1186","volume":"23","author":[{"given":"Karol M.","family":"Pencina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan D.","family":"Sniderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"Suppl 1","key":"2525_CR1","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/S0140-6736(15)60401-9","volume":"385","author":"A Dinesh Shah","year":"2015","unstructured":"Dinesh Shah A, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of a wide range of cardiovascular diseases: a cohort study in 1.9 million people. Lancet. 2015;385(Suppl 1):S86.","journal-title":"Lancet"},{"issue":"7","key":"2525_CR2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1800256","volume":"379","author":"A Rawshani","year":"2018","unstructured":"Rawshani A, Rawshani A, Franzen S, Sattar N, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, McGuire DK, Rosengren A, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379(7):633\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"2525_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1161\/ATVBAHA.116.306256","volume":"37","author":"K Yahagi","year":"2017","unstructured":"Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, Virmani R. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37(2):191\u2013204.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2525_CR4","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jcmg.2018.04.009","volume":"11","author":"U Kim","year":"2018","unstructured":"Kim U, Leipsic JA, Sellers SL, Shao M, Blanke P, Hadamitzky M, Kim YJ, Conte E, Andreini D, Pontone G, et al. Natural history of diabetic coronary atherosclerosis by quantitative measurement of serial coronary computed tomographic angiography: results of the PARADIGM study. JACC Cardiovasc Imaging. 2018;11(10):1461\u201371.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"2525_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jcct.2018.12.002","volume":"13","author":"KB Won","year":"2019","unstructured":"Won KB, Lee SE, Lee BK, Park HB, Heo R, Rizvi A, Lin FY, Kumar A, Hadamitzky M, Kim YJ, et al. Longitudinal assessment of coronary plaque volume change related to glycemic status using serial coronary computed tomography angiography: A PARADIGM (Progression of AtheRosclerotic PlAque determined by computed tomographic angiography imaging) substudy. J Cardiovasc Comput Tomogr. 2019;13(2):142\u20137.","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"2525_CR6","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice C: 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care 2024, 47(Suppl 1):S179-S218","DOI":"10.2337\/dc24-S010"},{"issue":"2","key":"2525_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"27","key":"2525_CR8","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1093\/eurheartj\/ehae258","volume":"45","author":"AD Sniderman","year":"2024","unstructured":"Sniderman AD, Dufresne L, Pencina KM, Bilgic S, Thanassoulis G, Pencina MJ. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention. Eur Heart J. 2024;45(27):2410\u20138.","journal-title":"Eur Heart J"},{"issue":"2","key":"2525_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/ije\/dym276","volume":"37","author":"P Elliott","year":"2008","unstructured":"Elliott P, Peakman TC, Biobank UK. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37(2):234\u201344.","journal-title":"Int J Epidemiol"},{"issue":"1","key":"2525_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/1559827615619159","volume":"12","author":"KI Galaviz","year":"2018","unstructured":"Galaviz KI, Narayan KMV, Lobelo F, Weber MB. Lifestyle and the prevention of type 2 diabetes: a status report. Am J Lifestyle Med. 2018;12(1):4\u201320.","journal-title":"Am J Lifestyle Med"},{"issue":"5","key":"2525_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/07315724.2005.10719479","volume":"24","author":"LA Bazzano","year":"2005","unstructured":"Bazzano LA, Serdula M, Liu S. Prevention of type 2 diabetes by diet and lifestyle modification. J Am Coll Nutr. 2005;24(5):310\u20139.","journal-title":"J Am Coll Nutr"},{"issue":"6","key":"2525_CR12","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa012512","volume":"346","author":"WC Knowler","year":"2002","unstructured":"Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes prevention program research G: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393\u2013403.","journal-title":"N Engl J Med"},{"issue":"9","key":"2525_CR13","first-page":"e46108","volume":"15","author":"D Patel","year":"2023","unstructured":"Patel D, Ayesha IE, Monson NR, Klair N, Patel U, Saxena A, Hamid P. The effectiveness of metformin in diabetes prevention: a systematic review and meta-analysis. Cureus. 2023;15(9):e46108.","journal-title":"Cureus"},{"issue":"4","key":"2525_CR14","doi-asserted-by":"publisher","first-page":"336","DOI":"10.2337\/ds18-0020","volume":"31","author":"VR Aroda","year":"2018","unstructured":"Aroda VR, Ratner RE. Metformin and type 2 diabetes prevention. Diabetes Spectr. 2018;31(4):336\u201342.","journal-title":"Diabetes Spectr"},{"issue":"9","key":"2525_CR15","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1002\/oby.23842","volume":"31","author":"L Wilkinson","year":"2023","unstructured":"Wilkinson L, Holst-Hansen T, Laursen PN, Rinnov AR, Batterham RL, Garvey WT. Effect of semaglutide 2 4 mg once weekly on 10-year type 2 diabetes risk in adults with overweight or obesity. Obesity (Silver Spring). 2023;31(9):2249\u201359.","journal-title":"Obesity (Silver Spring)"},{"key":"2525_CR16","doi-asserted-by":"crossref","unstructured":"American Diabetes A: 3. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020, 43(Suppl 1):S32-S36.","DOI":"10.2337\/dc20-S003"},{"issue":"12","key":"2525_CR17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","volume":"364","author":"RA DeFronzo","year":"2011","unstructured":"DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364(12):1104\u201315.","journal-title":"N Engl J Med"},{"issue":"7","key":"2525_CR18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.3390\/nu16071015","volume":"16","author":"S Dhokte","year":"2024","unstructured":"Dhokte S, Czaja K. Visceral adipose tissue: the hidden culprit for type 2 diabetes. Nutrients. 2024;16(7):1015.","journal-title":"Nutrients"},{"issue":"1","key":"2525_CR19","doi-asserted-by":"publisher","first-page":"258S","DOI":"10.3945\/ajcn.2009.28449C","volume":"91","author":"F Ziemke","year":"2010","unstructured":"Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2010;91(1):258S-261S.","journal-title":"Am J Clin Nutr"},{"issue":"11\u201312","key":"2525_CR20","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2119\/2008-00058.Rabe","volume":"14","author":"K Rabe","year":"2008","unstructured":"Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14(11\u201312):741\u201351.","journal-title":"Mol Med"},{"key":"2525_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1471-2350-14-54","volume":"14","author":"PJ Hsiao","year":"2013","unstructured":"Hsiao PJ, Chen ZC, Hung WW, Yang YH, Lee MY, Huang JF, Kuo KK. Risk interaction of obesity, insulin resistance and hormone-sensitive lipase promoter polymorphisms (LIPE-60 C > G) in the development of fatty liver. BMC Med Genet. 2013;14:54.","journal-title":"BMC Med Genet"},{"issue":"6","key":"2525_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-135-6-200109180-00014","volume":"135","author":"AD Sniderman","year":"2001","unstructured":"Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Ann Intern Med. 2001;135(6):447\u201359.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2525_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/01.ATV.19.3.743","volume":"19","author":"Z Zhang","year":"1999","unstructured":"Zhang Z, Cianflone K, Sniderman AD. Role of cholesterol ester mass in regulation of secretion of ApoB100 lipoprotein particles by hamster hepatocytes and effects of statins on that relationship. Arterioscler Thromb Vasc Biol. 1999;19(3):743\u201352.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2525_CR24","doi-asserted-by":"publisher","first-page":"13199","DOI":"10.3389\/jpps.2024.13199","volume":"27","author":"R Shang","year":"2024","unstructured":"Shang R, Rodrigues B. Lipoprotein lipase as a target for obesity\/diabetes related cardiovascular disease. J Pharm Pharm Sci. 2024;27:13199.","journal-title":"J Pharm Pharm Sci"},{"key":"2525_CR25","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.15420\/ecr.2023.16","volume":"18","author":"M Gabani","year":"2023","unstructured":"Gabani M, Shapiro MD, Toth PP. The role of triglyceride-rich lipoproteins and their remnants in atherosclerotic cardiovascular disease. Eur Cardiol. 2023;18:e56.","journal-title":"Eur Cardiol"},{"issue":"9","key":"2525_CR26","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3390\/nu15092105","volume":"15","author":"H Paublini","year":"2023","unstructured":"Paublini H, Lopez Gonzalez AA, Busquets-Cortes C, Tomas-Gil P, Riutord-Sbert P, Ramirez-Manent JI. Relationship between atherogenic dyslipidaemia and lipid triad and scales that assess insulin resistance. Nutrients. 2023;15(9):2105.","journal-title":"Nutrients"},{"issue":"1","key":"2525_CR27","doi-asserted-by":"publisher","first-page":"27146","DOI":"10.1038\/s41598-024-73672-6","volume":"14","author":"V Lamantia","year":"2024","unstructured":"Lamantia V, Bissonnette S, Beaudry M, Cyr Y, Rosiers CD, Baass A, Faraj M. EPA and DHA inhibit LDL-induced upregulation of human adipose tissue NLRP3 inflammasome\/IL-1beta pathway and its association with diabetes risk factors. Sci Rep. 2024;14(1):27146.","journal-title":"Sci Rep"},{"key":"2525_CR28","doi-asserted-by":"crossref","unstructured":"Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS, American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145(9):e722-59.","DOI":"10.1161\/CIR.0000000000001040"},{"key":"2525_CR29","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/ijms21051835","volume":"215","author":"A Poznyak","year":"2020","unstructured":"Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;215:1835.","journal-title":"Int J Mol Sci"},{"key":"2525_CR30","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3389\/fcvm.2020.00100","volume":"7","author":"A Nahmias","year":"2020","unstructured":"Nahmias A, Stahel P, Xiao C, Lewis GF. Glycemia and atherosclerotic cardiovascular disease: exploring the gap between risk marker and risk factor. Front Cardiovasc Med. 2020;7:100.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"2525_CR31","doi-asserted-by":"publisher","first-page":"C617","DOI":"10.1152\/ajpcell.00218.2022","volume":"323","author":"L Li","year":"2022","unstructured":"Li L, Wang M, Ma Q, Ye J, Sun G. Role of glycolysis in the development of atherosclerosis. Am J Physiol Cell Physiol. 2022;323(2):C617\u201329.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2525_CR32","doi-asserted-by":"publisher","first-page":"900254","DOI":"10.3389\/fimmu.2022.900254","volume":"13","author":"J Ye","year":"2022","unstructured":"Ye J, Li L, Wang M, Ma Q, Tian Y, Zhang Q, Liu J, Li B, Zhang B, Liu H, et al. Diabetes mellitus promotes the development of atherosclerosis: the role of NLRP3. Front Immunol. 2022;13:900254.","journal-title":"Front Immunol"},{"issue":"2","key":"2525_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/MED.0000000000000705","volume":"29","author":"MJ Chapman","year":"2022","unstructured":"Chapman MJ. HDL functionality in type 1 and type 2 diabetes: new insights. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):112\u201323.","journal-title":"Curr Opin Endocrinol Diabetes Obes"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02525-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02525-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T14:03:06Z","timestamp":1734616986000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02525-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2525"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02525-3","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"19 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Karol Pencina reports funding from the non-profit Doggone Foundation. Dr. George Thanassoulis has participated in advisory boards or speaker bureaus for Amgen, Regeneron\/Sanofi, HLS therapeutics, Ionis, Servier, Novartis, Silence and has received grant funding from Servier and Ionis. Dr. Michael Pencina reports funding from the non-profit Doggone Foundation, consulting fees from Cleerly Inc and advisory board fees from Eli Lilly and Janssen. Dr. Peter Toth is a member of the speaker\u2019s bureau for Amgen, Lilly, and Novo-Nordisk; he is a consultant to Lilly, Merck, and Novartis. Dr. Allan Sniderman has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"448"}}